Physician profile
Eve Johnson
NPI 1215453006
$5,989.23
in general payments reported to CMS, 2019-2025
46 companies · $2,231 in 2025
The $2,231 reported for 2025 was more than what 96% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $258 · 2022: $359 · 2023: $264 · 2024: $2,877 · 2025: $2,231.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,982 · Education: $390.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,981.76 |
| Education | $389.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $743.94 | 2024-2025 | Darzalex, Tecvayli, Talvey |
| Daiichi Sankyo INC. | $365.69 | 2024-2025 | Enhertu, Datroway, Injectafer |
| Pharmaessentia USA Corporation | $351.70 | 2024-2025 | Besremi |
| Astrazeneca Pharmaceuticals LP | $313.70 | 2024-2025 | Imfinzi, Calquence, Enhertu |
| Celgene Corporation | $294.85 | 2024-2025 | Reblozyl, Pomalyst |
| Astellas Pharma US INC | $285.93 | 2021-2024 | Padcev |
| Amgen INC. | $263.25 | 2021-2024 | |
| Sobi, INC | $252.79 | 2024-2025 | |
| Incyte Corporation | $231.14 | 2024-2025 | Monjuvi, Jakafi |
| Bayer Healthcare Pharmaceuticals INC. | $226.31 | 2024-2025 | |
| Medtronic, INC. | $189.88 | 2021-2023 | Venaseal |
| E.R. Squibb & Sons, L.L.C. | $180.36 | 2024-2025 | Opdivo, Reblozyl |
| Genzyme Corporation | $164.83 | 2023-2025 | |
| Sirtex Medical INC | $148.50 | 2024 | Sir-Spheres Microspheres |
| Regeneron Healthcare Solutions, INC. | $143.60 | 2021-2024 | Libtayo |
Show all 46 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eve Johnson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.